{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:58Z","timestamp":1781636098785,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007515","name":"Universidad de Valladolid","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007515","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpuse<\/jats:title>\n                    <jats:p>To compare dynamic risk stratification (DRS) according to the 2015 American Thyroid Association-Momesso et al. 2016 extension (ATA2015-M) and the 2025 ATA update in low-risk differentiated thyroid cancer (DTC) managed without radioactive iodine (I-131), and to explore the role of an intermediate thyroglobulin (Tg) cutoff of 1\u2009ng\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of a prospectively collected cohort of 74 low-risk DTC patients treated with total thyroidectomy (n\u2009=\u200955) or hemithyroidectomy (n\u2009=\u200919) between 2020 and 2024. Clinical, histopathological, and biochemical data were collected. DRS was assessed at the first follow-up visit (6 months after surgery) and at the last visit (median follow-up 27 months [IQR 16\u201341]) using ATA2015-M and ATA2025 criteria. An exploratory analysis applying a Tg cutoff of 1\u2009ng\/mL was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>According to ATA2015-M, excellent response (ER) rates in total thyroidectomy patients increased from 49.2% at baseline to 52.8% at final follow-up. In contrast, ATA2025 classified 89.1% as ER at baseline and 98.2% at final follow-up (p\u2009&lt;\u20090.001). Using the intermediate cutoff of 1\u2009ng\/mL, ER rates were 80.0% and 89.1%, respectively. Reclassification to ER under ATA2025 was primarily driven by anti-thyroglobulin antibody (TgAb) negativization, as Tg values remained stable and below the new 2.5\u2009ng\/mL threshold. No structural incomplete responses were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ATA2025 criteria substantially increase ER classification in low-risk DTC patients managed without I-131 compared with ATA2015-M. A 1\u2009ng\/mL Tg cutoff may provide a more realistic representation of clinical practice. The dynamic trend of TgAb, rather than their presence alone, is a key determinant for reclassification during follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-025-04548-6","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:43:02Z","timestamp":1771231382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative evaluation of dynamic risk stratification according to ATA 2015 and ATA 2025 in low-risk differentiated thyroid cancer without radioiodine ablation"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7710-0670","authenticated-orcid":false,"given":"Pablo","family":"Fern\u00e1ndez Velasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Peci\u00f1a Melgosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Torres Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Torres Morientes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Fern\u00e1ndez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Alonso Mesonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"de Uribe Viloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"\u00c1lvarez Qui\u00f1ones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Santos P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"de Luis Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-9412","authenticated-orcid":false,"given":"Gonzalo","family":"Diaz-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"11","key":"4548_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nrendo.2016.110","volume":"12","author":"CM Kitahara","year":"2016","unstructured":"C.M. Kitahara, J.A. Sosa, The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12(11), 646\u2013653 (2016). https:\/\/doi.org\/10.1038\/nrendo.2016.110","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"4548_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S2213-8587(21)00027-9","volume":"9","author":"A Miranda-Filho","year":"2021","unstructured":"A. Miranda-Filho, J. Lortet-Tieulent, F. Bray et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9(4), 225\u2013234 (2021). https:\/\/doi.org\/10.1016\/S2213-8587(21)00027-9","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"4548_CR3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363210.4","volume":"35","author":"MD Ringel","year":"2025","unstructured":"M.D. Ringel, J.A. Sosa, Z. Balach, L.A. Bischoff, G. Bloom, G.A. Brent, A.L. Brock, J.T. Broome, R.B. Flavell, W. Goldner, E.G. Grubbs, M.R. Haymart, S.M. Larson, A.M. Leung, J. Osborne, J.A. Ridge, B. Robinson, D.L. Steward, R.P. Tufano, L.J. Wirth, 2025 American Thyroid Association Management guidelines for adult patients with differentiated thyroid cancer. Thyroid 35(8), 841\u2013985 (2025). https:\/\/doi.org\/10.1177\/10507256251363210.4","journal-title":"Thyroid"},{"issue":"12","key":"4548_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"RM Tuttle","year":"2010","unstructured":"R.M. Tuttle, H. Tala, J. Shah et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the New American thyroid association staging system. Thyroid 20(12), 1341\u20131349 (2010). https:\/\/doi.org\/10.1089\/thy.2010.0178","journal-title":"Thyroid"},{"issue":"1","key":"4548_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1\u2013133 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"issue":"7","key":"4548_CR6","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1210\/jc.2015-4290","volume":"101","author":"DP Momesso","year":"2016","unstructured":"D.P. Momesso, F. Vaisman, S.P. Yang et al. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. J. Clin. Endocrinol. Metab. 101(7), 2692\u20132700 (2016). https:\/\/doi.org\/10.1210\/jc.2015-4290","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"4548_CR7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa2111953","volume":"386","author":"S Leboulleux","year":"2022","unstructured":"S. Leboulleux, C. Bournaud, C.N. Chougnet et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N. Engl. J. Med. 386(10), 923\u2013932 (2022). https:\/\/doi.org\/10.1056\/NEJMoa2111953","journal-title":"N. Engl. J. Med."},{"issue":"10498","key":"4548_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0140-6736(25)00629-4","volume":"406","author":"U Mallick","year":"2025","unstructured":"U. Mallick, K. Newbold, M. Beasley et al. Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial. Lancet 406(10498), 52\u201362 (2025). https:\/\/doi.org\/10.1016\/S0140-6736(25)00629-4","journal-title":"Lancet"},{"issue":"4","key":"4548_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","volume":"10","author":"M Pizzato","year":"2022","unstructured":"M. Pizzato, M. Li, J. Vignat et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10(4), 264\u2013272 (2022). https:\/\/doi.org\/10.1016\/S2213-8587(22)00035-3","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"4548_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","volume":"140","author":"L Davies","year":"2014","unstructured":"L. Davies, H.G. Welch, Current Thyroid Cancer Trends in the United States. JAMA Otolaryngol. Head. Neck Surg. 140(4), 317 (2014). https:\/\/doi.org\/10.1001\/jamaoto.2014.1","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"issue":"7","key":"4548_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1089\/thy.2013.0691","volume":"24","author":"TE Angell","year":"2014","unstructured":"T.E. Angell, C.A. Spencer, B.D. Rubino, J.T. Nicoloff, J.S. LoPresti, In Search of an Unstimulated Thyroglobulin Baseline Value in Low-Risk Papillary Thyroid Carcinoma Patients Not Receiving Radioactive Iodine Ablation. Thyroid 24(7), 1127\u20131133 (2014). https:\/\/doi.org\/10.1089\/thy.2013.0691","journal-title":"Thyroid"},{"key":"4548_CR12","doi-asserted-by":"publisher","unstructured":"Zavala L. F., Barra M. I., Olmos R., et al. In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation. Arch Endocrinol Metab. Published online April 15, 2019. https:\/\/doi.org\/10.20945\/2359-3997000000123","DOI":"10.20945\/2359-3997000000123"},{"issue":"8","key":"4548_CR13","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1210\/jc.2012-1123","volume":"97","author":"C Durante","year":"2012","unstructured":"C. Durante, T. Montesano, M. Attard et al. Long-Term Surveillance of Papillary Thyroid Cancer Patients Who Do Not Undergo Postoperative Radioiodine Remnant Ablation: Is There a Role for Serum Thyroglobulin Measurement? J. Clin. Endocrinol. Metab. 97(8), 2748\u20132753 (2012). https:\/\/doi.org\/10.1210\/jc.2012-1123","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"4548_CR14","doi-asserted-by":"publisher","first-page":"bvad102","DOI":"10.1210\/jendso\/bvad102","volume":"7","author":"JA Sipos","year":"2023","unstructured":"J.A. Sipos, J. Aloi, A. Gianoukakis et al. Thyroglobulin Cutoff Values for Detecting Excellent Response to Therapy in Patients With Differentiated Thyroid Cancer. J. Endocr. Soc. 7(9), bvad102 (2023). https:\/\/doi.org\/10.1210\/jendso\/bvad102","journal-title":"J. Endocr. Soc."},{"issue":"2","key":"4548_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.raem.2017.04.001","volume":"54","author":"E Abelleira","year":"2017","unstructured":"E. Abelleira, F. Bueno, A. Smulever, F. Pitoia, Riesgo din\u00e1mico en pacientes con c\u00e1ncer diferenciado de tiroides no ablacionados. Rev. Argentina de Endocrinolog\u00eda y. Metabolismo 54(2), 69\u201375 (2017). https:\/\/doi.org\/10.1016\/j.raem.2017.04.001","journal-title":"Rev. Argentina de Endocrinolog\u00eda y. Metabolismo"},{"issue":"5","key":"4548_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1530\/EJE-13-0386","volume":"169","author":"C Nascimento","year":"2013","unstructured":"C. Nascimento, I. Borget, F. Troalen et al. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur. J. Endocrinol. 169(5), 689\u2013693 (2013). https:\/\/doi.org\/10.1530\/EJE-13-0386","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"4548_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000442048","volume":"5","author":"CCPS Janovsky","year":"2016","unstructured":"C.C.P.S. Janovsky, R.M.B. Maciel, C.P. Camacho et al. A prospective study showing an excellent response of patients with low-risk differentiated thyroid cancer who did not undergo radioiodine remnant ablation after total thyroidectomy. Eur. Thyroid. J. 5(1), 44\u201349 (2016). https:\/\/doi.org\/10.1159\/000442048","journal-title":"Eur. Thyroid. J."},{"key":"4548_CR18","doi-asserted-by":"publisher","unstructured":"Ito Y., Miyauchi A., Yamamoto M., Kihara M., Onoda N., Mya A. Dynamic risk assessment using unstimulated serum thyroglobulin level and thyroglobulin doubling rate after total thyroidectomy for papillary thyroid carcinoma. Thyroid. 2025;35(10):\u2014 (Epub ahead of print). https:\/\/doi.org\/10.1177\/10507256251367242","DOI":"10.1177\/10507256251367242"},{"issue":"5","key":"4548_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/cbr.2019.3203","volume":"36","author":"M Araz","year":"2021","unstructured":"M. Araz, \u00c7. Soydal, E. \u00d6zkan et al. Role of thyroglobulin doubling time in differentiated thyroid cancer and its relationship with demographic-histopathologic risk factors and18 F-Fluorodeoxyglucose positron emission tomography\/computed tomography parameters. Cancer Biother Radiopharm 36(5), 425\u2013432 (2021). https:\/\/doi.org\/10.1089\/cbr.2019.3203","journal-title":"Cancer Biother Radiopharm"},{"issue":"7","key":"4548_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1089\/thy.2010.0355","volume":"21","author":"A Miyauchi","year":"2011","unstructured":"A. Miyauchi, T. Kudo, A. Miya et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 21(7), 707\u2013716 (2011). https:\/\/doi.org\/10.1089\/thy.2010.0355","journal-title":"Thyroid"},{"issue":"12","key":"4548_CR21","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1210\/jc.2008-0962","volume":"93","author":"WG Kim","year":"2008","unstructured":"W.G. Kim, J.H. Yoon, W.B. Kim et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 93(12), 4683\u20134689 (2008). https:\/\/doi.org\/10.1210\/jc.2008-0962","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"4548_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1089\/thy.2015.0445","volume":"26","author":"PW Rosario","year":"2016","unstructured":"P.W. Rosario, M.C. Tavares, G.F. Mour\u00e3o, M.R. Caldas, Comparison of antithyroglobulin antibody concentrations before and after ablation with 131I as a predictor of structural disease in differentiated thyroid carcinoma patients with undetectable basal thyroglobulin and negative neck ultrasonography. Thyroid 26(4), 525\u2013531 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0445","journal-title":"Thyroid"},{"issue":"9","key":"4548_CR23","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.endinu.2021.11.010","volume":"69","author":"ML Iglesias","year":"2022","unstructured":"M.L. Iglesias, J.M. Calabretta, O. Coggiola, I. Califano, Thyroglobulin antibodies: Trend over time and clinical impact in differentiated thyroid carcinoma with and without radioiodine ablation. Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n 69(9), 702\u2013708 (2022). https:\/\/doi.org\/10.1016\/j.endinu.2021.11.010","journal-title":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n"},{"issue":"2","key":"4548_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s12020-019-02112-7","volume":"67","author":"F Bueno","year":"2020","unstructured":"F. Bueno, M.G.G. Falcone, M.A. Pe\u00f1aloza, E. Abelleira, F. Pitoia, Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer. Endocrine 67(2), 387\u2013396 (2020). https:\/\/doi.org\/10.1007\/s12020-019-02112-7","journal-title":"Endocrine"},{"issue":"7","key":"4548_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/thy.2018.0080","volume":"28","author":"A Matrone","year":"2018","unstructured":"A. Matrone, F. Latrofa, L. Torregrossa et al. Changing trend of thyroglobulin antibodies in patients with differentiated thyroid cancer treated with total thyroidectomy Without131 I ablation. Thyroid 28(7), 871\u2013879 (2018). https:\/\/doi.org\/10.1089\/thy.2018.0080","journal-title":"Thyroid"},{"issue":"11","key":"4548_CR26","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1089\/thy.2012.0190","volume":"22","author":"PW Rosario","year":"2012","unstructured":"P.W. Rosario, A.F.C. Mineiro Filho, B.S.S. Prates, L.C.O. Silva, M.R. Calsolari, Postoperative stimulated thyroglobulin of less than 1 ng\/mL as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Thyroid 22(11), 1140\u20131143 (2012). https:\/\/doi.org\/10.1089\/thy.2012.0190","journal-title":"Thyroid"},{"issue":"2","key":"4548_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s12020-016-0989-3","volume":"54","author":"L Kashat","year":"2016","unstructured":"L. Kashat, S. Orlov, D. Orlov, J. Assi, F. Salari, P.G. Walfish, Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine. Endocrine 54(2), 460\u2013466 (2016). https:\/\/doi.org\/10.1007\/s12020-016-0989-3","journal-title":"Endocrine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04548-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04548-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04548-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:18:26Z","timestamp":1781633906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04548-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4548"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04548-6","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"77"}}